Publications - IR Sant Pau

Search

01/08/2021 Comment on "An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology''

Speeckaert, R, Lambert, J, Puig, L, Speeckaert, M, Lapeere, H, De Schepper, S, van Geel, N. Comment on "An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology''. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2021; 85(2)DOI:10.1016/j.jaad.2021.03.038. PMID:33744352. IF:15.487(Q1/1D).

01/08/2021 The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study

van Straalen, KR, Tzellos, T, Guillem, P, Benhadou, F, Cuenca-Barrales, C, Daxhelet, M, Daoud, M, Efthymiou, O, Giamarellos-Bourboulis, EJ, Jemec, GBE, Katoulis, AC, Koenig, A, Lazaridou, E, Marzano, AV, Matusiak, L, Molina-Leyva, A, Moltrasio, C, Pinter, A, Potenza, C, Romani, J, Saunte, DM, Skroza, N, Stergianou, D, Szepietowski, J, Trigoni, A, Vilarrasa, E, van der Zee, HH. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2021; 85(2)DOI:10.1016/j.jaad.2020.12.089. PMID:33484766. IF:15.487(Q1/1D).

01/08/2021 Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial

Puig, L, Bakulev, AL, Kokhan, MM, Samtsov, AV, Khairutdinov, VR, Morozova, MA, Zolkin, NA, Kuryshev, IV, Petrov, AN, Artemeva, AV, Zinkina-Orikhan, AV. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatology and Therapy. 2021; 11(4)DOI:10.1007/s13555-021-00554-4. PMID:34060012. IF:3.661(Q2/3D).

01/08/2021 Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab

Lambert, J, Hansen, JB, Sohrt, A, Puig, L. Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and Therapy. 2021; 11(4)DOI:10.1007/s13555-021-00545-5. PMID:33988818. IF:3.661(Q2/3D).

01/08/2021 Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model

Papp, KA, Soliman, AM, Done, N, Carley, C, Wirtz, EL, Puig, L. Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. Dermatology and Therapy. 2021; 11(4)DOI:10.1007/s13555-021-00550-8. PMID:34019229. IF:3.661(Q2/3D).

01/08/2021 Quality of Life in Hidradenitis Suppurativa: Validation of the HSQoL-24

Marron, SE, Gomez-Barrera, M, Aragones, LT, Goni-Navarro, A, Vilarrasa-Rull, E, Diaz-Diaz, RM, Garcia-Latasa De Aranibar, FJ, Campos-Rodenas, R, Fuentelsaz-Del Barrio, V, Gilaberte-Calzada, Y, Gracia-Cazana, T, Morales-Callaghan, AM, Ros-Abarca, S, Madrid-Alvarez, MB, Puig, L. Quality of Life in Hidradenitis Suppurativa: Validation of the HSQoL-24. ACTA DERMATO-VENEREOLOGICA. 2021; 101DOI:10.2340/00015555-3905. PMID:34427316. IF:3.875(Q2/3D).